A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers	Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Urogenital Diseases, Urogenital Neoplasms, astrocytoma (excluding glioblastoma), endocrine system disorder, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, glioblastoma, glioma, gonadal disorder, malignant endocrine neoplasm, neoplasm, neuroepithelial neoplasm, ovarian cancer, ovarian disorder, primitive neuroectodermal tumor, sarcoma, uterine disorder	Not yet recruiting	Phase 1 / Phase 2	2026-09-10		NCT07811297

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Advenchen Pharmaceuticals, LLC.	3

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
The University of Texas MD Anderson Cancer Center	Houston	United States	207